Abstract: This paper presents the architecture of the electronic detection and data processing (analysis) part, of a Lab-onChip (LoC) device. The data processing part focuses on the analysis of signals captured from the sensors used to detect possible mutations in the sample under consideration. The LoC consists of a micro-fluidics part for the sample preparation and hybridization, a micro-system part including the sensors for the hybridization electronic detection and finally a processing part for the data analysis and an interface for results presentation. The use of such LoCs aims at identifying the appropriate cluster of patients for a pharmacogenomic medicine based on the gene analysis results and at optimizing the effectiveness of the drug or determining whether the affected patient belongs to a group of patients who would suffer severe side effects.
I. INTRODUCTION
The recent deciphering of all human genes -a total of about 30,000 -by the Human Genome Project has made apparent that the genetic determinants for most, if not all common complex diseases could now be identified and evaluated. Such an evolution could lead to the post-genomic, individualized medicine that is not only going to improve health care but also influence in a profound way everyday life (nutrition, lifestyle factors, work, personal life, food etc.).
Lab-on-a-Chip devices (LoC) integrate multiple functions on one chip and make the analysis of human metabolism possible and easy, and may become an indispensable tool for clinicians, supporting their decisions for medication. Such devices integrate multiple functions, e.g. the extraction of the deoxyribonucleic acid (DNA) out of a sample of human tissue, the purification and amplification of this sample and finally the analysis based on microarrays.
DNA microarrays are ordered collections of microscopic spots (containing probes), arranged on a solid surface by covalent attachment to a chemical matrix. DNA hybridization, utilizing fluorophore-based detection, may prove to be a valuable tool both for expression profiling, i.e. monitoring the expression levels of many genes simultaneously, or for genotyping, e.g. clinical research for the investigation of disease-associated genes. The target substance undergoes some preprocessing prior to being applied onto the microarray, where so-called probe-target hybridization takes place.
Microarrays are a significant part of the Lab-on-Chip (LoC) for molecular diagnostics applications. Despite the wide use of microarrays in molecular biology and genetics, technical problems still exist, e.g. identifying and recognizing reliable data using image processing techniques. Currently, the data analysis is done with photographic methods and further quality assessment of the data after spot segmentation, thresholding between spot and background, grid matching, and noise suppression [1, 2] . This doesn't allow the full integration and operation as standalone devices for portable applications of microarrays (e.g. self-test). Electronic hybridization detection allows such an integration level but the reading of the array of the sensors with further data processing still remains an open issue [3] [4] [5] [6] . Moreover, nowadays the amount of sensors on the microarray may reach several thousands.
A fully integrated robust bio-diagnostics-electronic micro-system is presented that uses a disposable devicecartridge which first extracts the DNA from a blood drop, then it amplifies the fragmented tiny DNA samples using Polymerase Chain Reaction (PCR) and runs biological protocols that evaluate the analyzed substance; the application areas are pharmacogenomics, mutation detection for predisposition to specific diseases, molecular diagnosis of infectious diseases, virus molecular detection etc. It can be encapsulated in a single, portable, self-contained device-unit, significantly reducing the risks of cross-contamination inherent in conventional analysis methods. An embedded microprocessor monitors the process to perform hybridisation detection using a capacitive based micro-array structure. Subsequently, it initiates an automated methodology to execute normalization and removal of unreliable spot data.
II. STATE OF THE ART
It is expected that for years to come DNA screening will become a routine examination not only as diagnostic test for genetic defects but also to identify these gene variants and polymorphisms responsible for metabolic and predisposition characteristics having an impact on health. Hoffman-La Roche is now offering diagnosis of CYP450 gene variants, involved in drug metabolism and response, in a microarray developed with Affymetrix (AmpliChipCYP450 Test US-IVD package insert).
In the last 10 years, a large number of micro-and nanofluidic components, relying on a variety of working principles have been realized. Lab-on-a-Chip (LoC) or micro-Total Analysis Systems ( TAS) have been the focus of intense research (architectures discussed in [7] and in-depth reviews are presented in [8, 9] ). However, most of these solutions have not shown sufficient robustness for automated and integrated operation. Examples for these functions are sample delivery (macro-to-micro interface) and sample preparation, key problems in this context, for which a variety of solutions have been developed.
The research focuses on the three major parts of the process, namely the DNA extraction of the sample injected (or otherwise transferred) into the device, amplification of the extracted DNA in order to become detectable and hybridize and finally the detection itself, as well as the corresponding analysis of the outcome.
The sample delivery, being the first step in the overall cycle, represents the user-instrument interface and often is in the milliliter range. This volume has to be reduced to small quantities, which fit to the micro-fluidic structures on-chip [10, 11] . Using samples like blood, sputum, urine or even tissue a preliminary homogenization step is necessary to ensure reproducible results. This macro-scale homogenization has to be combined and adjusted with the micro-system. Volume reduction usually is accompanied by a preconcentration of the target molecules e.g. by size exclusion filters or affinity-chromatography.
After sample preparation target molecules have to be analyzed. If there is only a very small amount of target molecules amplification is used either on the target molecules themselves, e.g. via Polymerase Chain Reaction (PCR), or/and by using signal enhancement, e.g. fluorescence labeling. Detection systems have to be built up that meet the requirements of the micro-chip in means of miniaturization, geometry, reproducibility and sensitivity [12] .
A major challenge is encountered in the system integration problem. The full implementation of the advantages of micro-fluidic systems is due not only to the availability of components of moderate complexity, but also to the full integration of systems allowing the performance of a multitude of operations or the processing of a large number of fluidic samples in parallel.
In many application areas of micro-fluidics there is a specific demand for cheap and disposable, yet fully integrated systems allowing for multi-parameter assays of high sensitivity. Although a "toolbox" of miniaturized components already exists most approaches do not lead to market relevant Lab-on-a-chip solutions since the effort is too high (as discussed in [3] ). In many cases, polymers are the most suitable materials meeting these requirements. Polymer microsystems can be fabricated by technologies such as injection molding but with problems in reproducibility and also the assembly then with the detection part in silicon is costly.
Although individual functionalities may work alone the integration of several modules into one functional system is challenging. Specifications, e.g. flow rates or temperatures have to be adapted in a way that each module still fulfills its function but in the context of the whole assembly. The final integrated set-up has to perform all assay steps reproducible and repeatable. Therefore, a certain robustness of the system is mandatory as well as user friendliness.
In this work we are going to present a complete LoC solution enabling the wider use of molecular diagnostics for the adjustment of medication plans (e.g. drug dosage). After the initial presentation of the proposed methodology for processing the microarray data (an algorithm for evaluating the genotyping experiment carried out with the presented device), the sensor electronics and the integrated architecture are presented. At the end we show some indicative results related to the analysis of selected families of the Cytochrome P450, determining the metabolic capacity of a patient.
III. MICROFLUIDICS PART OF THE LOC MICROARRAY
DNA extraction and amplification are usually prerequisite steps necessary to provide a sufficient number of copies of the target gene sequences to enable visualization using specific detection modules, and thus identification or characterization of gene sequences. Conventional genetic analysis in clinical laboratories typically requires bench-top equipment and either manual or robotic transfer of liquids (e.g. 10-500uL) between tubes (or microwells in the case of microlitre plates) for separate steps of the process. Using conventional approaches, DNA extraction is most commonly implemented by initially rupturing the cells (cell lysis) in a buffer solution (e.g. a solution including sodium dodecyl sulphate (SDS)), then capturing the released DNA with either silica particles in a filter-type format, or silica-coated paramagnetic beads which can then be immobilized with a magnet. This allows all other cellular debris to be washed away, after which this "template" DNA can be eluted from the beads and re-suspended in a liquid buffer ready for amplification using the polymerase chain reaction (PCR). PCR involves cycling the DNA through a series of temperature levels using a programmable thermal cycler. Initially, the two strands of the template DNA duplex are separated by denaturation at ~95 o C, then short synthetic DNA "primer" sequences are annealed to the ends of the target section of template sequence (i.e. at a temperature usually between 50-60 o C), from which the Taq polymerase enzyme "zips" together the nucleotides present in the reaction mixture to build a new DNA sequence complementary to the template. By cycling the reaction through this process, usually between 25 and 40 times, the number of available copies of DNA to yield a sufficient of DNA is exponentially increased to enable detection and analysis. After sample preparation, conventional Quality Control (QC) of PCR reactions involves analysis of an aliquot of each reaction using agarose gel electrophoresis, to ensure that a fragment of DNA of the expected size was amplified. DNA analysis will continue either to identify specific sequences in specific parts of the DNA or to compare the expression of genes of various samples and extract results for the role of genes in specific diseases.
Microfluidics parts of LoCs usually implement these sample preparation steps fully automatically and the early years usually were made by silicon and glass. Nowadays a trend toward polymers as substrate material has been observed (for review see [13] ). Plastic substrates are less expensive and easier to manipulate in mass production than silica-based substrates.
Advances in polymer engineering have led recently to the development of a biochip device consisting of a plastic microfluidic chip, a printed circuit board (PCB), and a Motorola eSensor microarray chip. The plastic chip includes a mixing unit for rare cell capture using immunomagnetic separation, a cell pre-concentration-purification-lysis-PCR unit, and a DNA microarray chamber.
For the presented LoC composite materials based mainly on plastic foils (especially PDMS) and different types of fibers (especially silicon carbide fibers) are being used. A draft of the microfluidic part of the biochip is presented in Fig. (1) . The hybridization chamber hosting the electronic detection part of the LoC was designed taking into account various constraints and functions. The main chamber that accommodates the hybridisation of the sample DNA with the biological material of the spots is significantly reduced in size; it allows the measurement of all biological spots with pitch 300 m centre to centre and 170 m diameter spots. A heater controls and stabilizes temperature. The chamber should be isolated from external light and it should have the smallest auto fluorescence possible. The packaging of the chamber onto the sensors should be easy for the final assembly of the device. Probes grafting should be performed before the chamber assembly. Alignment between biological spots and sensors (optical way) should be ensured, while in the case of capacitive sensors this is not required. The whole system is compact and specil care is taken for optimized volumes (capillaries/hybridization chamber, tanks). It is characterized by low power consumption, robustness, waterproofness, and is of very low cost.
IV. ELECTRONIC DETECTION
Two alternative electronic detection approaches are evaluated. The first is using a photosensor and the other a capacitive sensor. Both produce 16 bits data for each spot of the microarray and are appropriate for the data analysis approach adopted here.
A. Photosensor Electronic Detection
Several protocols for microarray based SNP and mutation analysis have been developed (reviewed in [14] ) and the selected approach in the current LoC consists in tiled arrays [15] since these allow a variety of electronic detection techniques. Tiled arrays involve the generation of an array of oligos that vary in specific positions in order to create perfect matches to the fragmented DNA molecules which will bind strongly or mismatches that will result in weaker binding.
In the photo-detection context, tiled oligonucleotide arrays are suitable for single color detection [15] . The fragmented DNA molecules are labeled with a fluorophore probe and the more or less binding pairs result in relative intensities of the oligo spots that have to be compared. This requires the same amount of functional oligo to be deposited (by spotting) or synthesized [16] at each spot. The aim is to minimize variations in the amount of arrayed oligo, which will impede the analysis of single color intensities.
Optical Detection is one of the primary methods used for detection of hybridisation events, and in particular when fluorescence is used. The optical setup includes an excitation light source, typically LEDs or a laser, optical filters to separate the excitation light wavelength for the fluorescence wavelength and a detector. Here it is evaluated, a miniature photon counting optical detector solution that is a significant enabling tool for biochip based DNA detectors, enhancing the sensitivity of the optical detector by many orders of magnitude. This means that the quantities of DNA could be reduced significantly, the light emitting parameters of the fluorescence labels can be reduced resulting in the availability of new labels, and opening the possibility of direct detection of particular molecules. SensL develops a 2D array of photon counting sensors on a single chip that will enable detection of images of fluorescent hybridised DNA samples. It utilizes the high speed operation and low light level detection capability of the 2nd generation silicon detectors, the Geiger Mode-APD [17] . These devices produced using CMOS compatible processing are low power as appropriate for POC and portable applications and will have a low cost base.
These new developments in silicon photon counting detectors can eliminate costly optics and high power sources from medical equipment and provide higher levels of sensitivity at the same time.
B. Capacitive Sensor Electronic Detection
The other alternative investigated in the LoC under development is MEMS sensors based on mechanical movements and deformations of their micro-machined components, such as single-clamped suspended beams (cantilevers), double-clamped suspended beams (bridges), or suspended diaphragms.
In the development of the proposed LoC an approach for the detector array based on the stress induced on a thin silicon membrane due to reactions between the receptor DNA deposited on the membrane surface and the sample under investigation is explored.
Capacitive DNA Sensors Arrays based on the exploitation of surface stress changes and subsequent bending of an ultra silicon thin membrane are already fabricated. The membrane will seal the capacitor plates from the electrolyte solution thus enabling capacitive detection.
In this array each element of the array will be a capacitor comprised of an ultra thin silicon membrane suspended over a cavity and a counter electrode on the substrate. Operation of the device will rely on the induced stress due to the reaction between the receptor DNA a number of ultra thin silicon membranes covering a shallow cavity formed into a silicon dioxide layer etched on a silicon substrate containing the counter electrode of the capacitor detector. Silicon fusion bonding will be used to transfer the membrane over the cavity. A patented process is used for membrane fabrication.
The capacitive sensor microarray shown in Fig. ( 2) uses an innovative label free DNA sensing approach which exploits the surface stress changes arising during hybridization and the subsequent bending of an ultra thin silicon membrane. The membrane overhangs a small cavity and a counter electrode and effectively seals the capacitor plates from the electrolyte solution enabling capacitive detection. The operation of the device relies on the induced stress due to the reaction between the receptor DNA and the sample under investigation.
A special electronic circuit reads the array and converts capacitance changes into a frequency signal. Fig. (3) outlines the main blocks, where the coordinates (x, y) of each sensor to be read are externally driven by a controller described in the following sections.
The specifications of the circuit are presented in Table 1 .
V. SENSORS DATA PROCESSING ALGORITHM
Statistical analysis of microarray data is a major issue since it may deal some times with processing of massive amounts of data and also to adjust for various sources of variability in order to identify the existing mutations in the sample amongst the many that are questioned. The microarray LoC experiments here involve a number of distinct steps. An experiment is designed first, meaning that the genes to be examined are selected and particularly the exact sequences of bases (oligos) representing the mutations of the genes to be evaluated are determined. Those sequences are printed on the LoC to be hybridized and they are called here Muti.
Along with the mutant spots printed on the LoC the corresponding so called wild type sequences (oligos representing the interrogated sequences of a healthy sample) are also printed. Hereafter they are referred to as Wi. Another decision to be made during the design of an experiment is the number of replicates for each of the oligos on the LoC (mutant and wild type) taking into account both the available space on the microarray and the minimal number of spot replications necessary to guarantee an accurate result.
It is important to assess the quality of the data obtained from a microarray experiment [18, 19] , both on a global array basis and on an individual spot basis. The quality of the results from each microarray will vary with sample purity, variations in the printing process, success in carrying out the hybridization protocols and sensors' reliability. Control spots are present on each microarray. Null control spots such as blanks and printing buffers should have low values while house-keeping genes and titration series spots should show a range of higher values. Those control spots will be used at the beginning of the pre-processing for the acceptance of the experiment or not, then for the background correction values estimation and finally for the normalisation of the measurements. Concerning the acceptance or no of the experiment the mean values of the two kinds of control spots are calculated and in case of significant difference the experiment is retained. Outliers are identified for each of the mutations along with their associated wild type spots based on their relative values to the calculated standard deviation and mean value and they are excluded from further processing.
After hybridization several data processing steps of the LoC sensors' data follow. First the data must be processed to acquire mutant X and wild type of X spot values (MutXi, WXi where i is the index of the replica of the mutation X, appearing red and green in traditional microarrays), after subtracting background measurements for each spot. For that purpose the background values have to be calculated based on the mean value of the measurements of the designated spots that always do not hybridize. These spots are null spots that are designed appropriately so to never hybridise and are distributed as test spots evenly across the microarray surface. The number of these test and background estimation spots is Ns N = (where N is the total number of spots in the microarray). Measurements are corrected according to the background value so as to achieve less biased measurements for the hybridizations. The motivation for background adjustment is the belief that a spot's measured value includes a component not specifically due to the hybridization of the target to the probe, e.g. not specific hybridization. If such a component is present we would like to measure it and remove it to obtain more accurate quantification of the hybridization.
The acquired mutant/wild (red/green) ratios now after the background correction must be normalized to adjust for sensor-bias and for any systematic variation. The purpose of normalization is to adjust for any bias which arises from variation between spatial positions on a microarray. Hybridisation on different areas of the microarray may vary because of differences between the print-tips on the array printer, variation over the course of the print-run or non-uniformity in the hybridization. Hence it is necessary to normalize the intensities before any subsequent analysis is carried out. Normalization here is carried out by using designated control spots on the microarray. In the work presented here a microarray sample pool (MSP) titration series approach is deployed. MSP is analogous to genomic DNA as control with the exception that non-coding regions are removed. Theoretically all DNA sequences could hybridize to this mixed probe sample and it should be minimally subject to any sample-specific bias. The microarray area of Ns*Ns total spots is divided in subarrays of Ns * Ns and for each subarray one control spot is allocated. The value of this control spot is used to normalize the values of the spots in this subarray. Before normalization the logarithmic values of the measurements have to be calculated in order to avoid the divider later for the calculation of the normalized values: lgMutXi=log2(MutXi) and lgWXi= log2(WXi). Normalized lgMutXi = lgMutXi-lgCij and normalized lgWXi = lgWXilgCij, where ij is the subarray ID and lgCij is the log2Cij where Cij is the value of the titration series control spot of the specific ij subarray. Then, the normalized ratios are analyzed by various graphical and numerical means to decide about the existence of a mutation in a sample or to find groups of genes whose expression profiles can reliably classify the different RNA sources into meaningful groups.
After normalization of data the calculation of the Mutant to Wild ratios follows (calculation of M values), M= lgMutXi-lgWXi and the mean value is calculated over all replicas of each of the mutations analyzed by the microarray. The mean value and the standard deviation is calculated for a specific mutation X. This is the point where outliers' identification and exclusion takes place and a final Mean value is calculated for the M of this specific mutation X.
The existence or not of a mutation is decided using a statistic that will rank the mutations and their associated wild type from strongest to weakest evidence. After ranking the mutations a critical value for the ranking statistic is chosen, above which any value is considered to be significant. Assuming that there are n replicas of each mutant spot on the microarray, the absolute level of M is calculated, where M stands for the mean value of the M values for each of the n mutations and their associated wild type. Then the B-statistic is applied (an estimate of posterior log-odds that each mutation or wild type is expressed) that is equivalent to the penalized t-statistic: The proposed statistic has the advantage that it introduces some protection against outlier M-values and poor quality spots. Any MutX or WX value which is a non rejected outlier will give rise to a large standard deviation s which will prevent the mutation in question from being spuriously detected.
It is convenient to use base-2 logarithms for the ratio MutX/WX so that M is presented in units of 2-fold change. On this scale, M=0 represents equal expression (in case of agreement with the statistic test, in case the samples MutX and WX are alike), when in the case that the statistic test has shown that the samples MutX and WX are NOT alike, M=1 represents a 2-fold change between the RNA samples, M=2 represents a 4-fold change, and so on. After having decided the present mutations in the sample, the cluster assignment of the examined person will follow. There are tables provided about it and by using the results of the examination the person is allocated to a certain cluster according to predefined tables (such as the one found in AmpliChipCYP450 Test US-IVD).
The data produced by the developed LoC after hybridization are processed to infer if specific mutations are present in the examined sample and consequently to decide on what is the appropriate cluster that a patient should be assigned to. The examined array of the LoC consists of about 1600 sensors that are partitioned in groups; each group of sensors (probe) corresponds to a specific mutation that is examined. The accuracy of each sensor value is 16 bits which defines a range between 0 and 2 16 -1=65.535 and defines a dynamic range of 500-fold. Assuming that m groups of sensors yield from the partitioning, the same algorithm is applied to these m probes. Each group of sensors is divided in two parts: the part that is spotted with the wild type probes and the part spotted with the mutant probes. The calculations to be carried out on the data in a group of sensors (for both wild and mutant part), and the steps of the algorithm are depicted in the following diagram 1 in Fig. (4) .
The above steps 1-6 are repeated for all the groups of sensors in the in the LoC (all the mutations examined), and according to the predefined rules stored in the reference table the cluster where a patient belongs to is defined and an indication on the disposable LoC informs the physician or patient (at a later stage of integration), about this decision.
An indication FAIL will inform the physician in case the measurement has failed according to the quality measurements of the control spots.
VI. MULTI-CPU ARCHITECTURE ON FPGA FOR DATA ANALYSIS
The amount of data produced by large micro-arrays requires significant processing time especially when we desire more enhanced statistical analysis. The advent of advanced Field Programmable Gate Arrays (FPGA) in terms of speed and density provides maximal benefits in handling the large amounts of data. By taking advantage of the parallel computing resources in a single System-on-FPGA the data analysis can be performed in a fraction of time. Apparently, it is a safe strategy to also use the embedded FPGA to implement protocols and algorithms likely to change in the future (for example to support standards and evolving protocols not yet officially adopted). In this way, future changes are inherently easy to employ without changing the principal architecture of the System-on-FPGA. 1 The following notation is used: lgMutXi=log2(MutXi) and lgWXi= log2(WXi). Normalized lgMutXi = lgMutXi-lgCij and normalized lgWXi = lgWXi-lgCij, where ij is the sub-array ID, lgCij is the log2Cij and Cij is the value of the titration series control spot of the specific ij sub-array.
Fig. (4). Microarray data processing algorithm.

A. Internal Architecture
In this direction, to fully use the advances of this key technology -re-programmability, reusability and upgradeability -the system architecture needs to be a multi-CPU based data processing System-on-FPGA. The organization is shown in Fig. (4) . A soft-CPU based system (a CPU that can be synthesized and mapped on reconfigurable logic) consisting of eight MicroBlaze CPUs is developed to accommodate for the requirements of the microarray we use; the microarray is a four-by-four matrix of sub-arrays, while each one integrating one hundred sensors. The embedded System-on-FPGA that performs the data analysis is designed to interface the microarray device with four Interface Readers (IFRDs). Each such block is a simple circuitry responsible to send the retrieved values to the appropriate CPU; we have assigned one such IFRD block to each line of four sub-arrays.
For the evaluation scenario the data were artificially stored in small RAMs replacing the microarray shown in the system outline. The interface readers extract these data and forward them to the appropriate FIFO. Since replicas of the same gene are spotted in different sub-arrays the IFRDs must forward the corresponding values to the appropriate CPU. The right processing unit is indicated in a preconfigured field in the status register inside each IFRD. In the simulation experiments each CPU processes replicas of sixteen genes. The processing performed by each CPU consists of the sensor data processing algorithm described previously. Using a typical set of values the critical operations and their cost in terms of clock cycles are summarized in Table 2 . We opted for an area-efficient configuration of the MicroBlaze soft-processor, eliminating thus the need for integration of a floating-point or barrel shifter unit, but with carefully developed software functions. The logarithm function is actually a high-performance implementation as described in [20] using a 256 pre-computed lookup table. Finally, the calculation of the square root is also done with an approximation method, using the function: The first goal is to identify all existing mutations in the sample, subsequently identify the allele or alleles that are formed by these mutations and disambiguate multiple occurrences of the same mutation, and finally determine the type of metabolism based on the alleles detected. The t-values are usually a good indicator for the presence or absence of a mutation, especially when combined with the difference of means (i.e. when subtracting the mean value of all mutation readings against the wild type for a given polymorphism, the sign is the first indication, on which of the two is dominating). The measurements are unsigned 16-bit values ranging from 0 to 65536, the highest representing a better binding on the corresponding spot. The use of 16 bit values for the outcome of the electronic detection system was chosen so as to correspond to values using other detection techniques, such as the conventional image analysis, which deliver their outcome in the same range, thus making the last part of the processing chain much more flexible and independent of the actual detection technique.
The algorithm described in section 0 is implemented for a single wild and mutant spot that is for two set of values, each consisting of 16 replicas. The executable code, which is almost 40 KByte, is hosted in the local memory of one MicroBlaze CPU. An on-chip timer is used to measure the running time of the code in clock cycles, operating at 100 Mhz frequency.
First, to assess the tradeoff between accelerating the execution versus the cost in complexity, silicon area and overall system cost we performed various configurations. Three main directions are explored; enabling the hardware units inside the MicroBlaze CPU (Floating-point Unit, Barrel Shifter, etc), attaching a custom co-processor accelerator via Fast-Simplex-Link (FSL) and developing a multiple MicroBlaze CPU System-on-Chip. The results of acceleration the processing using a single MicroBlaze CPU are depicted in Fig. (6) . First, the least expensive solution in terms of area is depicted in the first set of columns. The logarithm function and the square root function are performed using software emulation and thus no hardware Floating Point (FP) unit is used. The second set of columns show the running time when the MicroBlaze is enhanced with an FP unit. Note that the impact of the log function is huge as is shown in the first column; this first column depicts the calculation of the log values of the 16 bit numbers that are fed to the CPU for processing. Hence, the third solution is the most beneficial in terms of performance, which utilizes the FP unit in concert with the approximation method in the previous subsection for calculating the square root function.
The multi-core embedded System-on-FPGA depicted in Fig. (5) is developed to perform the data analysis from the 1600-spot microarray using the same code as in the previous scenario. The principle difference is that the data are placed in advance to an external SRAM memory for evaluating the system performance. The results are plotted in Fig. (7) for two scenarios using four and eight CPUs. As the number of cores increases the speedup is not actually linear due to increased traffic over the shared PLB bus. However, even so, the provided bandwidth is enough to support real-time data processing on a single chip.
The results indicate that emerging Lab-on-Chip devices can employ relatively large microarrays and perform almost real-time diagnosis. Fig. (7) . Performance of the data processing algorithm on four and eight MicroBlaze CPUs.
VII. PHARMACOGENOMIC CASE
The case selected here to test the proposed architecture is the detection of genetic variations in the Cytochrome P450. Cytochrome P450 is a superfamily of hemoproteins found in almost all living creatures on earth (bacteria, archaea and eukaryotes). In humans, enzymes encoded by the CYP450 genes are found in many tissues. In the liver they metabolize drugs, toxins, and other foreign substances that enter the body. Through a process called "oxidative metabolism," the P450 enzymes enhance the water solubility of foreign compounds to aid in their excretion. For drugs, this process affects the blood levels of the therapeutic compound by enhancing clearance and in some cases, is a required step to convert an inactive pro-drug to it's active metabolite.
Humans have 57 genes and more than 59 pseudogenes divided among 18 families of cytochrome P450 genes and 43 subfamilies. For drug and steroid metabolism the family CYP2 plays and important role (it consists of 13 subfamilies, 16 genes and 16 pseudogenes). An important gene within this family is CYP2D6. The corresponding CYP2D6 enzyme activity can be extensively influenced by inherited variations as well as the effects of concurrent medications, which can inhibit enzyme activity and increase or decrease drug efficacy or adverse reactions. Another important gene is CYP2C19, involved in the metabolism of several important groups of drugs including many proton pump inhibitors and antiepileptics.
According to scientific research results, inherited genetic variations in the CYP2D6 and CYP2C19 genes can play an important role in how patients metabolize, and therefore respond to, many widely prescribed drugs. Knowledge of these variations can be used to help individualize drug treatment through selection of the more appropriate drugs and adjustment of dosages. These measures should improve medication outcome by reducing adverse drug reactions and improving drug efficacy. Additional applications include patient stratification for clinical trials for more effective and safer dosing.
The enzyme encoded by the CYP2D6 gene plays a primary role in the metabolism of drugs used to treat severe depression, schizophrenia, bi-polar disorder, cardiovascular disease treated with beta-blockers, attention deficit/hyperactivity disorder (ADHD), and others. The enzyme encoded by the CYP2C19 gene metabolizes many anti-convulsants, proton pump inhibitors, benzodiazepines, and anti-malarials. Both the CYP2D6 and CYP2C19 enzymes are involved in the metabolism of certain tricyclic antidepressant drugs used to treat depression.
Patients treated with drugs that are extensively metabolized by CYP2D6 and CYP2C19 enzymes are at increased risk for experiencing toxicity with standard dosing, while ultra-rapid metabolizers may not achieve therapeutic levels of the same drug in their blood with standard dosing. In the case of pro-drugs (drugs that require metabolic enzyme activity before they become the active therapeutic compound in the body), the opposite phenomenon occurs and poor metabolizers will experience no benefit from these drugs.
These variations will provide the associated predictive phenotype (poor, intermediate, extensive, or ultra-rapid metabolizer). More analytically:
• Extensive metabolizers (EM) -Possess at least one, and no more than two, normal functional alleles These genes are currently examined by the AmpliChip CYP450 Test of Roche-Affymetrix which detects 29 known polymorphisms in the CYP2D6 gene, including gene duplication and gene deletion, as well as two major polymorphisms in the CYP2C19 gene. Detection of these CYP2D6 polymorphisms results in the identification of 33 unique alleles, including seven CYP2D6 gene duplication alleles. To allow highly accurate prediction of patient phenotype, the proposed case should have the capability of detecting not just the presence of CYP2D6 gene duplications, but also the ability to discern which variation of the gene (allele) has been duplicated. This specificity is important in correctly predicting the ultra-rapid metabolizer phenotype and avoiding potential misclassification of the individuals tested. The current procedure using the Amplichip foresees the following steps:
The test may be ordered by a physician (if used as a diagnostic product) or is specified as part of a pharmaceutical clinical trial 2. The patient's sample is obtained. (For the AmpliChip CYP450 Test, a standard blood sample is required)
3.
The sample is sent to a laboratory trained in genetic analysis.
4.
Technician at laboratory begins by performing PCR amplification of selected segments of DNA extracted from the patient's sample.
VIII. RESULTS AND DISCUSSION
In the following we present the results of the application of the system presented herein to the CYP450 case. In order to increase the comparability of the results achieved, we have used a setup resembling the Roche/Affymetrix Amplichip. This means that out of the many polymorphisms for CYP2D6, we have selected the most frequent and important 27 alleles and additional three for CYP2C19 (including the wild type in both cases). In the detection of polymorphisms for determining the metabolism of a patient, there are numerous genes that can be examined. In order to increase comparability we will introduce in the following a test of two selected genes, namely CYP2D6 and CYP2C19, in accordance to the Roche/Affymetrix CYP450 Chip. Cytochrome P450 2D6 (CYP2D6) is one of the most important enzymes involved in the metabolism of xenobiotics in the body. There is considerable variability in its expression in the liver. Cytochrome P450 2C19 is also involved in the metabolism of xenobiotics in the body, mainly of several important groups of drugs including many proton pump inhibitors and anti-epileptics.
Each of the alleles is determined by one or more mutations in given positions or through repetitions/inversions of complete coding (and in some cases non-coding) segments. An example is the eighth allele (CYP2D6*8), in which case more mutations are present, namely 1758G>T, 1661G>C, 2850C>T and 4180G>C (the notation 1758G>T is read as follows: in position 1758 Guanine is replaced by Thymin). A mutation does not need to be specific for an allele and may be found in others, as well. The aforementioned 1661G>C mutation may also be found in other alleles, e.g. *19, *20 etc. A complete list of all alleles in the CYP450 family may be found in the home page of the Human Cytochrome P450 Allele Nomenclature Committee [21] , including also all references to the original publications, which present the mutations and their links to the phenotype of patients. This list is up to date and has served as the main reference for the creation of the assay used in the measurements, introducing a larger number of up-to-date polymorphisms, than typically used in past attempts (e.g. in the Affymetrix CYP450 AmpliChip).
Hence the goal is to firstly determine the mutations present in a sample out of the superset of mutations possible and then combine them to the two alleles in the sample of the patient (corresponding to the two chromosomes). The two alleles found are then used to conclude whether the patient is an ultrarapid, extensive, intermediate or poor metabolizer (looking up in a table the type of metabolism that this specific paired combination of alleles is typical for, e.g. in the table found in AmpliChipCYP450 Test US-IVD). If, for example, a sample contains no mutations and all genes are found to be of the wild type, one may conclude that the two alleles for this person are both *1 (no mutation), and in this case the person is a so called "extensive metabolizer". In a different example, having both alleles *9, the patient under consideration is an intermediate metabolizer, while the combinations of allele *11 and allele *15 leads to the conclusion that the patient is a poor metabolizer. The outcome of this consideration may help adjust the dosage of the medication (of course other aspects need to be taken into account, such as medical history etc.). A very good introduction on the personalization of medication and treatment based on the outcome of the CYP450 genetic testing may be found in [22] .
Since humans have pairs of chromosomes, it is possible that a polymorphism may affect only one of them (heterozygote), both of them (homozygote mutated) or none (homozygote). It is also possible that each chromosome may be affected by a different polymorphism (compound heterozygote). CYP2D6 is located on chromosome 22q13.1, while CYP2C19 is located on chromosome 10q24.
For our tests, we have used a conventional spotted microarray with 1600 spots (40*40), analyzing the data with a CCD sensor and subsequent image analysis. Based on the values obtained for each spot we extrapolated the anticipated values for the electronic detection method. The complete array was virtually separated in 16 subarrays (areas of 10*10 each), detecting 92 polymorphisms (including nine NULL spots and one titration spot per subarray). Each polymorphism was repeated 16 times on the microarray (corresponding to the number of the subarrays). The position of different probes in each of the subarrays was randomized, in order to avoid systematic errors and guarantee measurements of each probe in different areas of the microarray. If for instance the washing solution that is applied onto the microarray is staining a complete region, the values in this region are all useless. By distributing all values randomly in multiple areas of the microarray, the effect of such artifacts is reduced substantially.
We have investigated the outcome of the analysis for three different cases, namely a patient with seven polymorphisms, corresponding to the 4th allele of CYP2D6, a case with the same polymorphism on both chromosomes and finally two different polymorphisms, namely CYP2D6*4A and CYP2D6*41. As can be seen in the case of CYP2D6*A, there are more than one possible combinations of polymorphisms leading to the same allele, i.e. CYP2D6*4A through CYP2D6*4H and CYP2D6*4J through N, as well as CYP2D6*4X2. These different versions of the alleles exhibit slight differences, but are characterized by a core group of polymorphisms in common.
The first goal is to identify all existing mutations in the sample, subsequently identify the allele or alleles that are formed by these mutations and disambiguate multiple occurrences of the same mutation, and finally determine the type of metabolism based on the alleles detected. The t-values are usually a good indicator for the presence or absence of a mutation, especially when combined with the difference of means (i.e. when subtracting the mean value of all mutation readings against the wild type for a given polymorphism, the sign is the first indication, on which of the two is dominating). The measurements are unsigned 16-bit values ranging from 0 to 65536, the highest representing a better binding on the corresponding spot. The use of 16 bit values for the outcome of the electronic detection system was chosen so as to correspond to values using other detection techniques, such as the conventional image analysis, which deliver their outcome in the same range, thus making the last part of the processing chain much more flexible and independent of the actual detection technique.
In case the sample contains a given mutation in one of the alleles, it is expected to deliver a lower signal in the total of the 16 repetitions in both wild and mutant, since both probes for wild and mutant will be able to hybridize elements of the sample (some of the first chromosome and some of the second). Should the patient be a homozygote and exhibit the same mutations on both chromosomes, so will the values be increased for the mutation and decreased for the wild type. In all other cases, where there is no mutation present and the sample belongs to a homozygous wild type patient, the values are increased for the wild type probes and significantly decreased for the mutated spots. Fig. (8) . The outcome of the processing for a patient with the alleles CYP2D6*1 (wild type) and CYP2D6*4A; all gene alterations involved in CYP2D6*4A exhibit a lower value than the wild types of the other genes, since they are heterozygous and are included in the large circle in the lower left part; the mean values of the wild type and the mutation are similar and hence their logarithmized difference is close to zero; the t-values are for the affected genes also lower than the rest of the genes. Fig. (9) . The outcome of processing for a patient with the alleles CYP2D6*4A on both chromosomes (homozygous mutations) -note that the axis starts further right, when compared to the previous figure. The cluster of homozygous mutated genes appears clearly separated from the rest of the genes.
We have calculated according to the algorithm presented earlier the t-values for each polymorphism, comparing the wild type and mutant expressions. We are presenting the results of the processing in a modified volcano plot. The volcano plot is used frequently in gene expression experiments, where the wild type is compared against the mutant values. The idea behind the volcano plots is the efficient visualization of results in a manner that allows for a quick (visual) detection of genes that have a high and significant expression level. The volcano plot is basically a scatter plot, which compares the effect of a gene against its significance. The effect (x-axis) is computed as the (often logarithmized) difference between the means of the wild type and mutant measurements. The significance (y-axis) is often represented by the p-value of the t-test, while in some cases there are also versions considering the log-odds of the amount of wild type vs. mutant spots for each polymorphism (e.g. in [19] ). We are using a slightly modified version of the volcano plots for our genotyping experiments, where we represent the significance by the t-value itself. This allows us to identify the genes with high and significant levels in order to combine them into an allele (e.g. three specific polymorphisms will yield a specific allele, which will identify the type of metabolism of the patient under consideration). The outcome of three test-runs for each of the cases mentioned previously is presented in Figs. (8-10) . The deviations from the wild type are clearly visible. Fig. (10) . The case presented here is of a patient exhibiting the CYP2D6*4A and CYP2D6*41 alleles. The two genes that appear homozygous mutant in the diagram are the point mutations in positions 1661 and 4180, which appear in both alleles. The rest of the polymorphisms detected appear in heterozygous manner. In this case (allele *41 vs. *4A) the patient is classified as an intermediate metabolizer.
IX. CONCLUSIONS
Microarray data analysis is a time-consuming, cumbersome and often error-prone task. The present microsystem provides increased reliability by automating spot detection and data processing by on-chip dedicated highly integrated hardware. The automated methodology makes it hardly dependent on the operator skills, while the processing algorithm used in data analysis is able to result in accurate results. The data processing is performed in a fraction of time by a multi-CPU System-on-FPGA; this feature is attributed to the parallelization inherent in the data read from the microarray. Hence, exploiting this proposed SoC architecture it is possible to identify the existing mutations in the sample, subsequently identify the allele or alleles that are formed by these mutations and disambiguate multiple occurrences of the same mutation, and finally determine the type of metabolism based on the alleles detected.
